The two CAR T-cell products licensed by the FDA (ide-cel and cilta-cel) target the BCMA protein on the surface of myeloma cells and have shown efficacy in treating multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.